Has Arthur Molina, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,547 in general payments to Arthur Molina, MD across 62 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Arthur Molina, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Arthur Molina, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Arthur Molina, MD

Medical Oncology · Spokane, WANPI 1699718007

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,354 of the $1,547 with a category attached, or 87.5%. It is spread thinly across 27 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,056, more than ten times the $14 reported in 2019. That places this record below the midpoint for medical oncology clinicians in WA, where the typical reported total is $2,355.

$1,547in general payments, 2019–2025

Across 62 payments — averaging $24.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$209
GSK$146
Sanofi$141
Pfizer$130
Array Biopharma Inc$79
Sanofi-aventis U.S. LLC$78
plus $763 from 21 others

$204,731in research payments, 2019–2025

Across 9 payments — averaging $22,748 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$205K

What the payments were for

Food & beverage$1,35488%
Education$19312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	10	$209
GSK	7	$146
Sanofi	1	$141
Pfizer	6	$130
Array Biopharma Inc	4	$79
Sanofi-aventis U.S. LLC	1	$78
AstraZeneca	3	$77
Genentech USA, Inc.	2	$73
Gilead	4	$69
Eisai Inc.	3	$66
Daiichi Sankyo Inc.	2	$53
AbbVie	2	$51
Merck	2	$47
E.r. Squibb & Sons, L.L.C.	2	$43
EMD Serono, Inc.	1	$33
Beone Medicines USA, Inc.	1	$25
Astellas Pharma US Inc	1	$25
Acrotech Biopharma Inc.	1	$25
Myovant Sciences Inc.	1	$24
Exelixis Inc.	1	$24
Bristol Myers Squibb	1	$23
Mirati Therapeutics, Inc.	1	$23
Secura Bio, Inc.	1	$20
Johnson & Johnson	1	$17
Alnylam Pharmaceuticals Inc.	1	$17
Fennec Pharmaceuticals, Inc.	1	$16
Omeros Corporation	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SARCLISA$141

How this compares

$1,547 in reported general payments places this provider in the 45th percentile of 162 medical oncology providers in Washington.

See all medical oncology providers in Washington →

Medicare billing

Part B allowed, 2024

$778,504

Medicare patients

258

Services billed

27,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Anastrozole	66	$993
Ondansetron OdtOndansetron	41	$672
Morphine Sulfate ErMorphine Sulfate	21	$536
Letrozole	28	$439
Prochlorperazine Maleate	32	$407
Lidocaine-PrilocaineLidocaine/Prilocaine	14	$224
Tamoxifen Citrate	13	$149
Oxycodone Hcl	14	$115
Lorazepam	12	$93

Paid to pharmacies, not to this prescriber.

Other medical oncology in Spokane

Hakan KayaSpokane$2.2M
Mirela AndreiSpokane$22K
Bart ScottSeattle$1.3M
William BensingerLakewood$1.2M
Petros GrivasSeattle$628K
Vijayakrishna GadiSeattle$573K
Evan YuSeattle$296K
Siddhartha DevarakondaSeattle$215K
David MaloneySeattle$150K
Gary LymanSeattle$130K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →